AR038888A1 - Amidas heterociclicas - Google Patents
Amidas heterociclicasInfo
- Publication number
- AR038888A1 AR038888A1 ARP030100768A ARP030100768A AR038888A1 AR 038888 A1 AR038888 A1 AR 038888A1 AR P030100768 A ARP030100768 A AR P030100768A AR P030100768 A ARP030100768 A AR P030100768A AR 038888 A1 AR038888 A1 AR 038888A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydroxy
- alkoxy
- independently selected
- carbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Amidas heterocíclicas que poseen actividad inhibidora de la actividad de glucógeno fosforilasa y por lo tanto tienen valor en el tratamiento de estados de enfermedad con un aumento en la actividad de la glucógeno fosforilasa. También se describen procesos para la fabricación de dichos derivados de amidas heterocíclicas y composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) donde: la línea punteada es una unión simple o doble; X es N o CH; R4 y R5 juntos son -S-C(R6)=C(R7)=C(R6)-S-; R6 y R7 se seleccionan independientemente entre hidrógeno, halo, nitro, ciano, hidroxi, fluorometilo, difluorometilo, trifluorometilo, trifluorometoxi, carboxi, carbamoilo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4 y alcanoilo C1-4; A es fenileno o heteroarileno; n es 0, 1 ó 2; R1 se selecciona independientemente entre halo, nitro, ciano, hidroxi, carboxi, carbamoilo, N-alquilcarbamoilo C1-4, N,N-(alquil C1-4)2 carbamoilo, sulfamoilo, N-alquilsulfamoilo C1-4, N,N-(alquil C1-4)2sulfamoilo, -S(O)b alquilo C1-4 (donde b es 0, 1 ó 2), alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcanoilo C1-4, alcanoiloxi C1-4, hidroxi alquilo C1-4, fluorometilo, difluorometilo, trifluorometilo y trifluorometoxi; o, cuando n es 2, los dos grupos R1, junto con los átomos de carbono de A a los cuales están unidos, pueden formar un anillo de 4 a 7 miembros, que contiene opcionalmente 1 ó 2 heteroátomos seleccionados independientemente entre O, S y N, y estando opcionalmente sustituidos por uno o dos grupos metilo; R2 es hidrógeno, hidroxi o carboxi; R3 se selecciona independientemente entre hidrógeno, hidroxi, alcoxi C1-4, alcanoilo C1-4, carbamoilo, cicloalquilo C3-7 (opcionalmente sustituido con 1 ó 2 grupos hidroxi), ciano alquilo C1-4, arilo, heterociclilo, alquilo C1-4 (opcionalmente sustituido con 1 ó 2 grupos R8), y grupos de las fórmula (2) y (3) donde y es 0, ó 1; t es 0, 1, 2 ó 3 y u es 1 ó 2; con la salvedad de que el grupo hidroxi no es un sustituyente en el carbono del anillo adyacente al oxígeno del anillo; ó R8 se selecciona independientemente entre hidroxi, alcoxi C1-4 alcoxi C1-4; hidroxi alcoxi C1-4, acetales cíclicos de 5 y 6 miembros y derivados mono- y di-metilo de los mismos, arilo, heterociclilo, cicloalquilo C3-7, alcanoilo C1-4, alcoxi C1-4, alquil C1-4 S(O)b- (donde b es 0, 1 ó 2), cicloalquil C3-6 S(O)b- (donde b es 0, 1 ó 2), aril S(O)b- (donde b es 0, 1 ó 2), heterociclil S(O)b-(donde b es 0, 1 ó 2), bencil S(O)b- (donde b es 0, 1 ó 2), -N(OH)CHO, -C(=N-OH)NH2, -C(=N-OH)NH alquilo C1-4, -C(=N-OH)N(alquil C1-4)2, -C(=N-OH)NH cicloalquilo C3-6, -C(=N-OH)N(cicloalquil C3-6)2, -COCOOR9, -C(O)N(R9)(R10), -NHC(O)R9, -C(O)NHSO2(alquilo C1-4), -NHSO2R9, (R9)(R10)NSO2-, -COCH2OR11, (R9)(R10)N- y -COOR9; R9 y R10 se seleccionan independientemente entre hidrógeno, hidroxi, alquilo C1-4 (opcionalmente sustituido por 1 ó 2 R13), cicloalquilo C3-7(opcionalmente sustituido por 1 ó 2 grupos hidroxi), ciano alquilo C1-4, trihalo alquilo C1-4, arilo, heterociclilo y heterociclil alquilo C1-4; o R9 y R10 junto con el nitrógeno, a los cuales están unidos forman un anillo de 4 a 6 miembros donde el anillo es opcionalmente sustituido en un carbono por 1 ó 2 sustituyentes independientemente seleccionados entre oxo, hidroxi, carboxi, halo, nitro, ciano, carbonilo, alcoxi C1-4 y heterociclilo; ó el anillo puede ser opcionalmente sustituido en dos carbonos adyacentes por -O-CH2-O- para formar un acetal cíclico donde uno ó ambos hidrógenos del grupo -O-CH2-O- pueden ser reemplazados por un metilo; R13 se selecciona entre halo, trihalometilo, y alcoxi C1-4; R11 se selecciona independientemente entre hidrógeno, alquilo C1-4, y hidroxi alquilo C1-4; o una sal aceptable para uso farmacéutico o prodroga del mismo; con la salvedad de que el compuesto de fórmula (1) no es: i) 2,3-dicloro-5-[N-(2-oxo-1,2,3,4-tetrahidroquinol-3-il)carbamoil]-4H-tien[3,2-b]pirrol; ii) 2-cloro-5-[N-(2-oxo-1,2,3,4-tetrahidroquinol-3-il)carbamoil]-6H-tien[2,3-b]pirrol; o iii) 2-cloro-5-[N-(1-metil-2-oxo-1,2,3,4-tetrahidroquinol-3-il)carbamoil]-6H-tien[2,3-b]pirrol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0205165.4A GB0205165D0 (en) | 2002-03-06 | 2002-03-06 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038888A1 true AR038888A1 (es) | 2005-02-02 |
Family
ID=9932329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100768A AR038888A1 (es) | 2002-03-06 | 2003-03-06 | Amidas heterociclicas |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7129249B2 (es) |
| EP (1) | EP1483270A1 (es) |
| JP (1) | JP2005526058A (es) |
| KR (1) | KR20040096661A (es) |
| CN (1) | CN100384852C (es) |
| AR (1) | AR038888A1 (es) |
| AU (1) | AU2003214377A1 (es) |
| BR (1) | BR0308146A (es) |
| CA (1) | CA2477667A1 (es) |
| GB (1) | GB0205165D0 (es) |
| IL (1) | IL163803A0 (es) |
| MX (1) | MXPA04008614A (es) |
| NO (1) | NO20043852L (es) |
| NZ (1) | NZ534990A (es) |
| PL (1) | PL372973A1 (es) |
| TW (1) | TW200305412A (es) |
| WO (1) | WO2003074532A1 (es) |
| ZA (1) | ZA200406679B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| CA2495943C (en) * | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0320422D0 (en) * | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
| PL380887A1 (pl) | 2003-12-29 | 2007-04-02 | Sepracor Inc. | Pirolowe i pirazolowe inhibitory DAAO |
| US7402674B2 (en) | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| US7498341B2 (en) * | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| JP2007519648A (ja) * | 2004-01-31 | 2007-07-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ７−フェニルアミノ−４−キノロン−３−カルボン酸誘導体、その製造方法及び医薬としての使用 |
| WO2006055463A2 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055462A1 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7314882B2 (en) | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| DE102005063244A1 (de) * | 2005-12-21 | 2007-06-28 | Eberhard-Karls-Universität Tübingen | Modifiziertes 2-Nitroimidazol-Derivat |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| CN104276955A (zh) | 2006-01-06 | 2015-01-14 | 赛诺维信制药公司 | 基于四氢萘酮的单胺再摄取抑制剂 |
| WO2007082026A2 (en) * | 2006-01-10 | 2007-07-19 | The Trustees Of Boston College | Catalytic enantioselective silylations of substrates |
| ES2555315T3 (es) | 2006-03-31 | 2015-12-30 | Sunovion Pharmaceuticals Inc. | Preparación de amidas y aminas quirales |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| WO2011047320A2 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
| TW201726630A (zh) * | 2009-10-16 | 2017-08-01 | 梅林塔療法公司 | 抗微生物性化合物及其製造與使用方法 |
| MX2017011616A (es) | 2015-03-11 | 2018-04-11 | Melinta Therapeutics Inc | Compuestos antimicrobianos y métodos para hacerlos y usarlos. |
| US11098047B2 (en) | 2016-05-06 | 2021-08-24 | BioVersys AG | Antimicrobials and methods of making and using same |
| CN109553580B (zh) * | 2017-09-25 | 2023-08-11 | 南京长澳医药科技有限公司 | 硝基咪唑类化合物中间体及其盐的制备方法 |
| CN112442022B (zh) * | 2019-09-02 | 2022-05-20 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE200740C (es) | ||||
| US3706810A (en) | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4692522A (en) | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4720503A (en) | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| US4599198A (en) | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4668769A (en) | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| JPH02124756A (ja) | 1988-07-27 | 1990-05-14 | Suzuki Sangyo Kk | セメンティング組成物 |
| JPH04179949A (ja) | 1990-11-15 | 1992-06-26 | Fuji Photo Film Co Ltd | 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料 |
| CA2137832C (en) | 1992-06-12 | 2000-09-26 | Dennis J. Hoover | Inhibitors of angiotensin i chymase(s) including human heart chymase |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| EP0749423B1 (en) | 1994-03-09 | 2003-06-18 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| FR2723739B1 (fr) | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| DE4445968A1 (de) | 1994-12-22 | 1996-06-27 | Bayer Ag | Verwendung von Sulfonylguanazinen |
| JP3314938B2 (ja) | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体 |
| AP9600817A0 (en) | 1995-06-06 | 1996-07-31 | Pfizer | Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt. |
| ES2164151T3 (es) | 1995-06-06 | 2002-02-16 | Pfizer | N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa. |
| IL124109A (en) | 1995-09-08 | 2001-10-31 | Novo Nordisk As | Pharmaceutical composition of 2-alkylpyrrolidines for use in the manufacture of medicaments for the treatment of diabetes |
| AU2090897A (en) | 1996-02-29 | 1997-09-16 | Mikael Bols | Hydroxyhexahydropyridazines |
| EP0914322A1 (en) | 1996-05-27 | 1999-05-12 | Fujisawa Pharmaceutical Co., Ltd. | New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| US5952322A (en) | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| EP0946587A2 (en) | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
| AU6291098A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | Novel heterocyclic compounds |
| EP0983239A1 (en) | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Novel heterocyclic compounds |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
| WO2000042213A1 (en) | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
| AU2535700A (en) | 1999-02-12 | 2000-08-29 | Novo Nordisk A/S | Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation |
| US6043091A (en) | 1999-07-19 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense modulation of liver glycogen phosphorylase expression |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| WO2001023347A1 (en) | 1999-09-29 | 2001-04-05 | Novo Nordisk A/S | Novel aromatic compounds |
| EP1088824B1 (en) | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| PL200167B1 (pl) | 1999-11-05 | 2008-12-31 | Sod Conseils Rech Applic | Związki heterocykliczne o aktywności hamowania kalpain i/lub pułapkowania ROS, ich zastosowanie i kompozycje farmaceutyczne je zawierające oraz związki pośrednie |
| DK1741445T3 (da) | 2000-01-21 | 2013-11-04 | Novartis Ag | Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| AR028253A1 (es) | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| DK1145717T3 (da) | 2000-04-13 | 2004-08-02 | Pfizer Prod Inc | Synergistisk virkning af glyburid og milrinon |
| SK17252002A3 (sk) | 2000-06-09 | 2003-05-02 | Aventis Pharma Deutschland Gmbh | Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo |
| US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| WO2002026714A1 (fr) | 2000-09-27 | 2002-04-04 | Takeda Chemical Industries, Ltd. | Composes spiraniques |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| US6933317B2 (en) | 2000-11-01 | 2005-08-23 | Shionogi & Co. Ltd. | PGD2 receptor antagonistic pharmaceutical compositions |
| AU2002256053A1 (en) | 2001-04-04 | 2002-10-21 | Genzyme Corporation | Novel bgp compounds for therapy and diagnosis and methods for using same |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| AU2002308706A1 (en) | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| WO2003037864A1 (fr) | 2001-10-29 | 2003-05-08 | Japan Tobacco Inc. | Compose indolique, et utilisation a des fins therapeutiques |
| US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| WO2003091213A1 (fr) | 2002-04-25 | 2003-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amide ou sels de ces derives |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| WO2004041780A2 (en) | 2002-11-07 | 2004-05-21 | Pfizer Products Inc. | N-(indole-2-carbonyl) amides as anti-diabetic agents |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| JP2004196702A (ja) | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| WO2004092158A1 (en) | 2003-04-17 | 2004-10-28 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
| BRPI0409952A (pt) | 2003-04-30 | 2006-04-25 | Pfizer Prod Inc | agentes anti-diabéticos |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| GB0318464D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318463D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020985A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| WO2005020986A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
| GB0320422D0 (en) | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-03-06 GB GBGB0205165.4A patent/GB0205165D0/en not_active Ceased
-
2003
- 2003-03-04 KR KR10-2004-7013863A patent/KR20040096661A/ko not_active Application Discontinuation
- 2003-03-04 PL PL03372973A patent/PL372973A1/xx not_active Application Discontinuation
- 2003-03-04 JP JP2003573000A patent/JP2005526058A/ja not_active Withdrawn
- 2003-03-04 IL IL16380303A patent/IL163803A0/xx unknown
- 2003-03-04 WO PCT/GB2003/000877 patent/WO2003074532A1/en active Application Filing
- 2003-03-04 US US10/506,741 patent/US7129249B2/en not_active Expired - Fee Related
- 2003-03-04 EP EP03709947A patent/EP1483270A1/en not_active Withdrawn
- 2003-03-04 CN CNB038102145A patent/CN100384852C/zh not_active Expired - Fee Related
- 2003-03-04 CA CA002477667A patent/CA2477667A1/en not_active Abandoned
- 2003-03-04 AU AU2003214377A patent/AU2003214377A1/en not_active Abandoned
- 2003-03-04 BR BR0308146-0A patent/BR0308146A/pt not_active IP Right Cessation
- 2003-03-04 NZ NZ534990A patent/NZ534990A/en unknown
- 2003-03-04 MX MXPA04008614A patent/MXPA04008614A/es active IP Right Grant
- 2003-03-05 TW TW092104650A patent/TW200305412A/zh unknown
- 2003-03-06 AR ARP030100768A patent/AR038888A1/es unknown
-
2004
- 2004-08-23 ZA ZA200406679A patent/ZA200406679B/en unknown
- 2004-09-14 NO NO20043852A patent/NO20043852L/no not_active Application Discontinuation
-
2006
- 2006-08-08 US US11/463,144 patent/US7276517B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL372973A1 (en) | 2005-08-08 |
| ZA200406679B (en) | 2005-01-18 |
| BR0308146A (pt) | 2004-12-07 |
| KR20040096661A (ko) | 2004-11-16 |
| EP1483270A1 (en) | 2004-12-08 |
| CN1653070A (zh) | 2005-08-10 |
| NO20043852L (no) | 2004-09-14 |
| MXPA04008614A (es) | 2004-12-06 |
| CN100384852C (zh) | 2008-04-30 |
| TW200305412A (en) | 2003-11-01 |
| WO2003074532A1 (en) | 2003-09-12 |
| US7276517B2 (en) | 2007-10-02 |
| IL163803A0 (en) | 2005-12-18 |
| US7129249B2 (en) | 2006-10-31 |
| GB0205165D0 (en) | 2002-04-17 |
| JP2005526058A (ja) | 2005-09-02 |
| US20070043069A1 (en) | 2007-02-22 |
| NZ534990A (en) | 2006-02-24 |
| AU2003214377A1 (en) | 2003-09-16 |
| US20050131015A1 (en) | 2005-06-16 |
| CA2477667A1 (en) | 2003-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038888A1 (es) | Amidas heterociclicas | |
| AR038887A1 (es) | Amidas heterociclicas | |
| AR038886A1 (es) | Amidas heterociclicas, inhibidores de actividad de glucogeno fosforilasa | |
| AR038889A1 (es) | Amidas heterociclicas | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| AR074902A1 (es) | Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1 | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| TW200745117A (en) | Macrocylic inhibitors of hepatitis C virus | |
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR045955A1 (es) | Compuestos benzoimidazolicos | |
| NO974586L (no) | Nye substituerte bifenyl- eller fenylpyridinforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholder dem | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| AR039648A1 (es) | Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen | |
| RU2004109812A (ru) | Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| UA97639C2 (ru) | ОКТАГИДРОПИРОЛО[3,4-b]ПИРРОЛЬНЫЕ ПРОИЗВОДНЫЕ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ ГИСТАМИНА-3 | |
| AR044116A1 (es) | Compuestos derivados de 5,7 diamino pirazolo [4,3-d] pirimidinas, intermediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la fabricacion de medicamentos. | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |